DURHAM, NC and LONDON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Polarean, a commercial-stage medical imaging company advancing functional MRI of the lungs, today announced the expansion of its Xenon MRI ...

Europe’s easing of AI and data rules could unlock faster innovation. Tech experts detail the AI use cases most likely to ...

WASHINGTON, DC—On Wednesday at the American Chemical Society Fall 2025 meeting, students and seasoned drug hunters alike gathered in a spacious third-floor ballroom of the Walter E. Washington ...

Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...

The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced formulation design, real-time dose flexibility, and cutting-edge CMC expertise ...

In the final part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his December column, ...

The U.S. Food and Drug Administration (FDA) issued its third Patient-Focused Drug Development (PFDD) guidance titled, “Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments ...

Two formative experiences shaped Craig Crews’ path into drug development. First, when he was still a child, his grandmother died from cancer at just 52 years old. “At the time, there weren’t very many ...

The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...